Riyadh is the site of the launch of the New Accelerator Program for Drugs in Rare Diseases (NADR), a regulatory initiative to support the development of and access to medicines for rare diseases.
According to SPA, the Saudi Food and Drug Authority (SFDA) designed the program to empower researchers and developers while advancing healthcare innovation. The initiative operates within the SFDA regulatory framework to streamline the evaluation, authorization, and development of these drugs.
The NADR designation targets drugs for life-threatening, seriously debilitating, or rare diseases defined by a prevalence of fewer than 5 in 10,000 persons in Saudi Arabia. Eligibility requires that no satisfactory treatment exists in the country, or the product provides clinical benefit over current options. Eligible products may be under active development or authorized by other regulatory authorities but not yet registered in Saudi Arabia.
The SFDA provides a package of support measures, including dedicated regulatory and scientific guidance and streamlined manufacturer site registration. The program also includes flexible requirements for periodic safety update reports and innovative approaches to evaluating clinical evidence to address challenges with small patient populations.
What is the NADR program launched by the SFDA? The New Accelerator Program for Drugs in Rare Diseases (NADR) is a specialized regulatory initiative launched by the SFDA in Riyadh. It is designed to support the development of medicines for rare diseases and empower researchers and developers. The program operates within the SFDA regulatory framework to streamline the authorization, evaluation, and development of drugs to accelerate patient access to critical treatments.
Which drugs are eligible for the NADR designation? Drugs are eligible if they treat or prevent a seriously debilitating, life-threatening, or rare disease, which is defined as affecting fewer than 5 in 10,000 people in Saudi Arabia. Additionally, the product must offer clinical benefit over current options or have no satisfactory treatment available in the country. Eligible products can be already authorized by other regulatory authorities or be under active development at any stage.
What regulatory incentives does the NADR program provide? The SFDA provides a tailored package of support including streamlined procedures for manufacturer site registration and dedicated scientific and regulatory guidance. The program also offers flexible requirements for periodic safety update reports where appropriate. Furthermore, it utilizes innovative and flexible approaches to evaluate clinical evidence, specifically accounting for the difficulties associated with small patient populations.